154 related articles for article (PubMed ID: 34620694)
1. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
Yu J; Wang Y; Ragueneau-Majlessi I
Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
[TBL] [Abstract][Full Text] [Related]
2. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
4. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
[TBL] [Abstract][Full Text] [Related]
5. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
[TBL] [Abstract][Full Text] [Related]
6. Risk of Enzyme- and Transporter-Mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2024 May; ():. PubMed ID: 38734524
[TBL] [Abstract][Full Text] [Related]
7. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
8. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
9. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model.
Asano S; Kurosaki C; Mori Y; Shigemi R
Drug Metab Pharmacokinet; 2024 Feb; 54():100531. PubMed ID: 38064927
[TBL] [Abstract][Full Text] [Related]
10. In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018.
Yu J; Ragueneau-Majlessi I
Clin Transl Sci; 2020 Jul; 13(4):693-699. PubMed ID: 31981398
[TBL] [Abstract][Full Text] [Related]
11. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
Umeyama Y; Fujioka Y; Okuda T
Xenobiotica; 2014 Dec; 44(12):1135-44. PubMed ID: 24937160
[TBL] [Abstract][Full Text] [Related]
12. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
[TBL] [Abstract][Full Text] [Related]
15. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
18. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
19. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
20. Prediction methods of drug-drug interactions of non-oral CYP3A4 substrates based on clinical interaction data after oral administrations - Validation with midazolam, alfentanil, and verapamil after intravenous administration and prediction for blonanserin transdermal patch.
Tomita Y; Yahata M; Hashimoto M; Nishimuta H; Kawaguchi H; Matsushita H; Kitamura A; Nishibe H; Natsui K; Watanabe T
Drug Metab Pharmacokinet; 2020 Aug; 35(4):345-353. PubMed ID: 32660818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]